AGTR1 and metabolic dysfunction-associated steatotic liver disease: Ang II/AT1R was determined to promote NAFLD, and previous studies have illustrated that AT1R blockade can ameliorate fatty liver and that AT1R blockers can potentially be used for NAFLD therapy11,12.